![Angelo S. Botter](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Perfil
Angelo S.
Botter worked as a Director at Advanced Viral Research Corp.
from 2006 to 2009 and at Medexus Pharmaceuticals, Inc. from 2013 to 2014.
He obtained an undergraduate degree from McGill University.
Antiguos cargos conocidos de Angelo S. Botter.
Empresas | Cargo | Fin |
---|---|---|
MEDEXUS PHARMACEUTICALS INC. | Director/Miembro de la Junta | 02/06/2014 |
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Director/Miembro de la Junta | 23/03/2009 |
Formación de Angelo S. Botter.
McGill University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
MEDEXUS PHARMACEUTICALS INC. | Health Technology |
Empresas privadas | 1 |
---|---|
Advanced Viral Research Corp.
![]() Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Health Technology |
- Bolsa de valores
- Insiders
- Angelo S. Botter